Floatz logo

Thalidomide

Maintenance Treatment

Henan Cancer HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Maintenance Treatment cohort.

Asset / SponsorPhaseRating
Toripalimab
Taizhou Hospital
Phase 3B
Catequentinib
Taizhou Hospital
Phase 3B
Venetoclax
Henan Cancer Hospital
N/AD
INTERFERON ALPHA 1B
Henan Cancer Hospital
N/AD
Azacitidine
Henan Cancer Hospital
N/AD

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →